We use cookies on this site to enable your digital experience. By continuing to use this site, you are agreeing to our cookie policy. close

Fed. Circ. Upholds Most Patents For Allergan Glaucoma Drug

Law360, New York (May 2, 2013, 3:06 PM EDT) -- The Federal Circuit ruled Wednesday that only one of the four patents for Allergan Inc.'s glaucoma drug Combigan was invalid, partly reversing a lower court’s decision but still preventing Sandoz Inc....
To view the full article, register now.